Following a lengthy R&D process, two new molecules from Biogen could add much-needed treatments for a disease that’s been difficult to pin down.

Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...

Biogen beat Wall Street estimates for third-quarter profit, helped by better-than-expected sales of some of its multiple ...

As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company ...

The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.

Discover Biogen's Q3 2025 earnings: 67% launch product growth, strategic pipeline expansion, and updated guidance amid evolving market dynamics.

Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to ...

Garg, recently named to BioSpace’s 40 Under 40, proved her mettle managing one of the toughest partnerships out there: the ...

Biogen Inc (BIIB) reports robust financial performance with significant growth in launch products and a focus on expanding its pipeline for future success.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...

C5aR1 plays an important role in the immune cascade that causes tissue inflammation, particularly in neutrophil-mediated conditions. There’s an obvious overlap with Biogen’s own izastobart, an ...